TNFα but not IL-17 is critical in the pathogenesis of rheumatoid arthritis spontaneously occurring in a unique FcγRIIB-deficient mouse model

References

• Connor JR, Dodds RA, James IE, Gowen M. Human osteoclast and giant cell differentiation: the apparent switch from NSE to TRARP activity coincides with the in situ expression of osteopontin mRNA. J Histochem Cytochem. 1995;43(12):1193–201.
   PubMedGoogle Scholar
• Dodds RA, Connor JR, Drake FH, Gowen M. Expression of cathepsin K messanger RNA in giant cells and their precursors in human osteoarthritic synovial tisseus. Arthritis Rheum. 1999;42(8):1588–93.
   PubMedGoogle Scholar
• Boyle W, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423(6937):337–42.
   PubMedGoogle Scholar
• Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5(12):953–64.
   PubMed Web of Science ®Google Scholar
• Takayanagi H. Osteoimmunology and the effect of the immune system on bone. Nat Rev Rheumatol. 2009;5(12):667–76.
   PubMedGoogle Scholar
• Walsh MC, Kim N, Kadono Y, Rho J, Lee SY, Choi Y. Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol. 2006;24:33–63.
   PubMed Web of Science ®Google Scholar
• Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med. 2006;203(12):2673–82.
   PubMedGoogle Scholar
• Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309–19.
   PubMed Web of Science ®Google Scholar
• Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, et al. T-cell-mediated regulation of osteoclastogenesis by signaling cross-talk between RANKL and IFN-γNature. 2000;408(6812):600–5.
   PubMedGoogle Scholar
• Maini RN, Elliott MJ, Brennan FM, Feldmann M. Beneficial effects of tumor necrosis factor-alpha (TNF-α) blockade in rheumatoid arthritis (RA). Clin Exp Immunol. 1995;101(2):207–12.
   PubMedGoogle Scholar
• Taylor PC. Anti-tumor necrosis factor therapies. Curr Opin Rheumatol. 2001;13(3):154–9.
   Google Scholar
• Zwerina J, Redlich K, Schett G, Smolen JS. Pathogenesis of rheumatoid arthritis: targeting cytokines. Ann N Y Acad Sci. 2005;1051:715–29.
   Google Scholar
• Catrina AI, af Klint E, Ernestam S, Catrina SB, Makrygiannakis D, Botusan IR, et al. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. Arthritis Rheum. 2006;54(1):76–81.
   PubMedGoogle Scholar
• Voll RE, Kalden JR. Do we need new threatment that goes beyoun tumor necrosis factor blockers for rheumatoid arthritis?Ann N Y Acad Sci. 2005;1051:799–810.
   PubMed Web of Science ®Google Scholar
• Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA. Involvement of endogenous tumor necrosis factor α and transforming growth factor β during induction of collagen type II arthritis in mice. Proc Natl Acad Sci USA. 1992;89(16):7375–79.
   PubMedGoogle Scholar
• Piguet PF, Grau GE, Vesin C, Loetscher H, Gentz R, Lesslauer W. Evolution of collagen arthritis in mice is arrested by treatment with antitumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology. 1992;77(4):510–14.
   PubMedGoogle Scholar
• Campbell IK, O’Donnell K, Lawlor KE, Wicks IP. Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. J Clin Invest. 2001;107(12):1519–27.
   PubMedGoogle Scholar
• Ji H, Pettit A, Ohmura K, Oriz-Lopez A, Duchatelle V, Degott C, et al. Critical roles for interleukin 1 and tumor necrosis factor a in antibody-induced arthritis. J Exp Med. 2002;196(1):77–85.
   PubMedGoogle Scholar
• Iwakura Y, Nakae S, Saijo S, Ishigame H. The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev. 2008;226:57–79.
   PubMed Web of Science ®Google Scholar
• Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Ann Rev Immnol. 2009;27:485–517.
   PubMed Web of Science ®Google Scholar
• O’Quinn D, Palmer M, Lee Y, Weaver C. Emergence of the Th17 pathway and its role in host defense. Adv Immunol. 2008;99:115–63.
   PubMed Web of Science ®Google Scholar
• Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology. 2010;129(3): 311–21.
   PubMed Web of Science ®Google Scholar
• Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastgenesis. J Clin Invest. 1999;103(9):1345–52.
   PubMedGoogle Scholar
• Nakae S, Saijo S, Horai R, Sudo K, Mori S, Iwakura Y. IL-17 production from activated T cells is required for the spontaneous development of arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci USA. 2003;100(10):5986–90.
   PubMed Web of Science ®Google Scholar
• Hirota K, Hashimoto M, Yoshitomi H, Tanaka S, Nomura T, Yamaguchi T, et al. T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis. J Exp Med. 2007;204(1):41–7.
   PubMed Web of Science ®Google Scholar
• Nakae S, Nambu A, Sodo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol. 2003;171(11):6173–7.
   PubMed Web of Science ®Google Scholar
• Doodes PD, Cao Y, Hamel KM, Wang Y, Farkas B, Iwakura Y, Finnegan A. Development of proteoglycan-induced arthritis is independent of IL-17. J Immunol. 2008;181(1):329–37.
   PubMedGoogle Scholar
• Delgado-Vega A, Sánchez E, Löfgren S, Castillejo-López C, Alarcón-Riquelme ME. Recent findings on genetics of systemic autoimmune diseases. Curr Opin Immunol. 2010;22(6):698–705.
   PubMedGoogle Scholar
• Sato-Hayashizaki A, Ohtsuji M, Lin Q, Hou R, Ohtsuji N, Nishikawa K, et al. Presumptive role of 129 strain-derived Sle16 locus for rheumatoid arthritis in a new mouse model with FcγRIIB-deficient C57BL/6 genetic background. Arthritis Rheum. 2011;63(10):2930–8.
   PubMedGoogle Scholar
• Bolland S, Ravetch JV. Spontaneous autoimmune disease in FcγRIIB-deficient mice results from strain-specific epistasis. Immunity. 2000;13(2):277–85.
   PubMedGoogle Scholar
• Nimmerjahn F, Ravetch JV. Antibody-mediated modulation of immune responses. Immunol Rev. 2010;236:265–75.
   PubMed Web of Science ®Google Scholar
• Kawano S, Lin Q, Amano H, Kaneko T, Nishikawa K, Tsurui H, et al. Phenotype conversion from rheumatoid arthritis to systemic lupus erythematosus by introduction of Yaa mutation into FcγRIIB-deficient G57BL/6 mice. Eur J Immunol. 2013;43(3):770–8.
   PubMedGoogle Scholar
• Takai T, Ono M, Hikida M, Ohmori H, Ravetch JV. Augmented humoral and anaphylactic responses in FcγRII-deficient mice. Nature. 1996;379(6563):346–9.
   PubMedGoogle Scholar
• Nakae S, Komiyama Y, Nambu A, Sudo K, Iwase M, Homma I, et al. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity. 2002;17(3):375–87.
   PubMedGoogle Scholar
• Taniguchi T, Takada M, Ikeda A, Momotani E, Sekigawa K. Failure of germinal center formation and impairment of response to endotoxin in tumor necrosis factor α-deficient mice. Lab Invest. 1997;77(6): 647–58.
   PubMedGoogle Scholar
• Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity. 2003;19(1):71–82.
   PubMedGoogle Scholar
• Kim MS, Day CJ, Morrison NA. MCP-1 is induced by receptor activator of nuclear factor-κB ligand, promotes human osteoclast fusion, and rescues granulocyte macrophage colony-stimulating factor suppression of osteoclast formation. J Biol Chem. 2005;280(16):16163–9.
   PubMedGoogle Scholar
• van den Berg WB, Mclnnes IB. Th17 cells and IL-17 A-Focus on immunopathology and immunotherapeutics. Semin Arthritis Rheum. 2013;43(2):158–70.
   PubMedGoogle Scholar
• Pisitkun P, Ha HL, Wang H, Claudio E, Tivy CC, Zhou H, et al. Interleukin-17 cytokines are critical in development of fetal lupus glomerulonephritis. Immunity. 2012;37(6):1104–15.
   PubMedGoogle Scholar
• Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, et al. Induction of intestinal TH17 cells by segmented filamentous bacteria. Cell. 2009;139:485–98.
   PubMed Web of Science ®Google Scholar
• Marino MW, Dunn A, Grail D, Inglese M, Noguchi J, Richards E, et al. Characterization of tumor necrosis factor-deficient mice. Proc Natl Aca Sci USA. 1997;94(15):8093–8.
   PubMedGoogle Scholar
• Sweet RA, Christensen SR, Harris ML, Shupe J, Sutherland JL, Shlomchik MJ. A new site-directed transgenic rheumatoid factor mouse model demonstrates extrafollicular class switch and plasmablast formation. Autoimmunity. 2010;43(8):607–18.
   PubMedGoogle Scholar
• Ravetch JF, Kinet PJ. Fc receptors. Annu Rev Immunol. 1991;9:457–92.
   PubMed Web of Science ®Google Scholar
• Takai T. Roles of Fc receptors in autoimmunity. Nat Rev Immunol. 2002;2(8):580–92.
   PubMedGoogle Scholar
• Santiago-Raber ML, Amano H, Amano E, Baudino L, Otani M, Lin Q, et al. FcγR-dependent expansion of a hyperactive monocyte subset in lupus-prone mice. Arthritis Rheum. 2009; 60(8):2408–17.
   PubMedGoogle Scholar
• Kikuchi S, Santiago-Rober ML, Amano H, Amano E, Fossati-Jimack L, Moll T, et al. Contribution of NZB autoimmunity 2 to Y-linked autoimmune acceleration-induced monocytosis in association with murine systemic lupus. J Immunol. 2006;176(5):3240–7.
   PubMedGoogle Scholar
• Yao Z, Li P, Zhang Q, Schwarz EM, Keng P, Arbini A, et al. Tumor necrosis factor-α increases circulating osteoclast precursor numbers by promoting their proliferation and differentiation in the bone marrow through up-regulation of c-Fms expression. J Biol Chem. 2006;281(17):11846–55.
   PubMedGoogle Scholar
• Yun TJ, Chaudhary PM, Shu GL, Frazer JK, Ewings MK, Schwartz SM, et al. OPG/FDCR-1. A TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol. 1998;161(11):6113–21.
   PubMedGoogle Scholar
• Zannettio ACW, Holding CA, Diamond P, Atkins GJ, Kostakis P, Farrugia A, et al. Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol. 2005; 204(2):714–23.
   PubMedGoogle Scholar